title: Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy.
abstract: We report the case of a 43-year-old male patient with persistent multifocal, skin-restricted, CD30-positive, large T-cell lymphoma. Combination therapy of systemic interferon alfa and oral bexarotene was initiated on an experimental basis in the hope of circumventing therapies such as methotrexate, radiotherapy, or multiple-agent chemotherapy that may be required in such cases. This treatment was associated with rapid and marked regression of the patient's cutaneous lesions.
authors.affiliation: Department of Dermatology, University of Pennsylvania, Philadelphia, USA. french@cmu.unige.ch
authors.forename: L E
authors.initials: LE
authors.lastname: French
authors.forename: M
authors.initials: M
authors.lastname: Shapiro
authors.forename: J M
authors.initials: JM
authors.lastname: Junkins-Hopkins
authors.forename: C C
authors.initials: CC
authors.lastname: Vittorio
authors.forename: A H
authors.initials: AH
authors.lastname: Rook
mesh_terms: D000284:Administration, Oral; D000328:Adult; D016588:Anticarcinogenic Agents / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000077610:Bexarotene; D004359:Drug Therapy, Combination; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D017730:Ki-1 Antigen / Q000032:analysis*; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage*
chemical_list: D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D016898:Interferon-alpha; D017730:Ki-1 Antigen; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene